Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2023 · New England Journal of Medicine · 469 citations
https://doi.org/10.1056/nejmoa2312054
A
Aurore Perrot
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
439
Papers
11.1K
Citations
43
h-index
143
i10-index
Aurore Perrot is an academic researcher from Institut universitaire du cancer de Toulouse Oncopole. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 43, co-authored 374 publications.
ORCID: 0000-0003-0131-8689Papers by this author
worksLocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
2022 · Leukemia · 233 citations
https://doi.org/10.1038/s41375-022-01531-2
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03050-2
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
2025 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03485-7
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
2025 · Nature Reviews Clinical Oncology · 72 citations
https://doi.org/10.1038/s41571-025-01041-x
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
2018 · Leukemia · 71 citations
https://doi.org/10.1038/s41375-018-0133-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat